Tradestie Institutional Equity Comparison Engine

HCM vs AVDL โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

AVDL Overall Edge

AVDL Captures Institutional Edge (4โ€“0 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Avadel Pharmaceuticals plc Ordinary Share (AVDL) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, HCM trades at N/M Forward P/E with -6.3% operating margin (+0.2% YoY revenue) versus AVDL at 28.8x Forward P/E and 2.5% operating margin (+54.9% YoY). In options structure, HCM sits in UNCLASSIFIED (73rd %ile IV; Dealer Gamma Walls on Pro) against AVDL sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner AVDL
HCM N/M vs AVDL 28.8x Fwd P/E
Growth & Margin Winner AVDL
Op Margin -6.3% vs 2.5% ยท YoY +0.2% vs +54.9%
Momentum & Technical Winner AVDL
1Y -9.8% vs +138.1% ยท 52W Pos 53% vs 89%
Options & Structure Winner AVDL
UNCLASSIFIED (73rd %ile IV) vs UNCLASSIFIED (<1st %ile IV)
HCM NASDAQ
HUTCHMED (China) Limited American Depositary Shares
Pharmaceutical Preparations
$13.22
-1.71% 1D
Market Cap $2.3B
1M Return -7.42%
1Y Return -9.82%
Forward P/E N/M
Unified AI Score
38.1 / 100 SELL
Tech 31.0 Fund 44.0 Flow 50.0 Mom 56.0
AVDL NASDAQ
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
$21.64
+0.05% 1D
Market Cap $2.1B
1M Return +0.65%
1Y Return +138.06%
Forward P/E 28.8x
Unified AI Score
62.9 / 100 BUY
Tech 75.0 Fund 60.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: HCM -9.82% AVDL +138.06% Spread: +8.74 pp (HCM Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
HCM TTM Op. Margin: -6.3% AVDL TTM Op. Margin: 2.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HCM vs AVDL. Trailing 12-month operating profitability (HCM -6.3% vs AVDL 2.5%) and valuation multiples (HCM N/M vs AVDL 28.8x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: HCM (3) vs AVDL (7)
Institutional Metric HCM AVDL Criterion Row Winner
Market Capitalization Scale $2.3B $2.1B Larger Scale HCM
Trailing P/E Ratio Valuation 134.0x 16.8x Lower Multiple AVDL
Forward P/E Ratio Valuation N/M 28.8x Lower Multiple AVDL
Revenue Growth (YoY) Growth +0.2% +54.9% Higher Growth AVDL
Operating Margin (TTM) Profitability -6.3% 2.5% Higher Margin AVDL
Net Profit Margin Profitability 3.3% -0.1% Higher Margin HCM
Return on Equity (ROE) Capital Efficiency 1.5% -0.3% Higher ROE HCM
52-Week Range Position Momentum 53% ($10โ€“$16) 89% ($6โ€“$24) Stronger Trend AVDL
Beta / 30D Volatility Risk Regime 0.64ฮฒ ยท 45% Vol 0.14ฮฒ ยท 2% Vol Lower Realized Risk AVDL
Unified Institutional Score Composite Signal 38.1 / 100 (SELL) 62.9 / 100 (BUY) Higher Composite AVDL

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full HCM vs AVDL Buy Guide
HCM UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 73rd %ile
IV Regime Elevated (60thโ€“80th %ile)
Live HCM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
AVDL UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live AVDL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither HCM nor AVDL registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.